| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Eugonia |
| Information provided by: | Eugonia |
| ClinicalTrials.gov Identifier: | NCT00417157 |
Purpose
The purpose of this study is to evaluate the effectiveness of a modified natural cycle in patients with previous poor response to infertility drugs, prior to proceeding to oocyte donation or abandoning fertility treatment.
| Condition | Intervention | Phase |
|
Infertility Premature Ovarian Failure |
Drug: recombinant FSH (Puregon, Organon, The Netherlands) Drug: GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands) Drug: hCG (Pregnyl, Organon, The Netherlands) |
Phase IV |
| MedlinePlus related topics: | Infertility Premature Ovarian Failure |
| Drug Information available for: | Follitropin beta Urofollitropin Chorionic gonadotropin Choriogonadotropin Alfa Gonadorelin Gonadorelin hydrochloride LH-RH Ganirelix acetate Ganirelix |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
| Official Title: | Successful Application of Modified Natural Cycle in Poor Responders Prior to Oocyte Donation |
| Estimated Enrollment: | 48 |
| Study Start Date: | October 2003 |
| Estimated Study Completion Date: | November 2006 |
Poor responders are a diverse group of IVF patients who fail to respond to IVF drugs. In these patients pregnancy rates remain disappointingly low and usually oocyte donation is their only viable option. The need for lengthy ovarian stimulation regimes can be avoided by performing IVF during a natural menstrual cycle. However, the main problem with a natural cycle is that successful IVF outcome can be compromised by a premature LH surge. This problem can be solved by the administration of GnRH antagonists that suppress endogenous gonadotropin levels, comprising a modified natural cycle (MNC). Previous studies have shown that MNC offers no realistic chances of pregnancy prior to oocyte donation. In this study we will re-assess this view by showing that MNC offers some, albeit small, chances of positive IVF outcome in patients with known previous poor response prior to oocyte donation.
Eligibility
| Ages Eligible for Study: | 30 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| Study ID Numbers: | MNC |
| First Received: | December 22, 2006 |
| Last Updated: | December 28, 2006 |
| ClinicalTrials.gov Identifier: | NCT00417157 |
| Health Authority: | Greece: National Organization of Medicines |
|
|
|
|
|
